Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shirley Wong

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
BJUI Compass|September 17, 2025
Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in AustraliaAlison Hiong, James Lynam, Andrew Weickhardt, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2022
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysisGrace Chazan, Angelyn Anton, Shirley Wong, et al.
International Journal of Cancer|March 17, 2021
Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease settingLouise Kostos, Wei Hong, Belinda Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2021
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational studyAngelyn Anton, Shirley Wong, Julia Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
Journal of Geriatric Oncology|September 8, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohortMichael Fernando, Angelyn Anton, Andrew Weickhardt, et al.
Asia-Pacific Journal of Clinical Oncology|September 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive diseaseAndrew Schmidt, Angelyn Anton, Julia Shapiro, et al.
BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
Gynecologic Oncology|July 15, 2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancerIgnace Vergote, Russell J Schilder, Charles H Pippitt, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
BJUI Compass|September 17, 2025
Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in AustraliaAlison Hiong, James Lynam, Andrew Weickhardt, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2022
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysisGrace Chazan, Angelyn Anton, Shirley Wong, et al.
International Journal of Cancer|March 17, 2021
Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease settingLouise Kostos, Wei Hong, Belinda Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2021
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational studyAngelyn Anton, Shirley Wong, Julia Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
Journal of Geriatric Oncology|September 8, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohortMichael Fernando, Angelyn Anton, Andrew Weickhardt, et al.
Asia-Pacific Journal of Clinical Oncology|September 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive diseaseAndrew Schmidt, Angelyn Anton, Julia Shapiro, et al.
BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
Gynecologic Oncology|July 15, 2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancerIgnace Vergote, Russell J Schilder, Charles H Pippitt, et al.
Pageof 8